表紙
市場調査レポート

抗血栓薬/血液凝固阻止剤:技術と世界市場

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

発行 BCC Research 商品コード 254864
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
抗血栓薬/血液凝固阻止剤:技術と世界市場 Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets
出版日: 2013年01月01日 ページ情報: 英文 109 Pages
概要

世界の抗血栓薬/血液凝固阻止剤の市場は高齢化や血栓イベントの増加、医薬品の発展などの影響因子により変化を遂げています。

当レポートでは、抗血栓薬/血液凝固阻止剤の技術と市場について調査分析し、薬剤タイプ・地域別の収益実績・予測、主要製品、競合分析、主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 産業概要

  • 循環器系
  • 症状
  • 止血 (凝結法)
  • 血栓塞栓症に関連する疾患
  • ステントと血栓症
  • 人口動態
  • 静脈血栓塞栓症とライフスタイル
  • 静脈血栓塞栓症と空の旅

第4章 血液凝固阻止剤

  • 概要
  • 製品
  • 世界市場の規模・成長率
  • 成長率:地域別
  • 成長率:薬剤タイプ別
  • 競合分析

第5章 抗血小板物質

  • 概要
  • 製品
  • 世界市場の規模・成長率
  • 成長率:地域別
  • 成長率:薬剤タイプ別

第6章 トロンビン阻害剤

  • 概要
  • 製品
  • 世界のトロンビン阻害剤市場の市場規模・成長率
  • トロンビン阻害剤の成長率:地域別
  • 成長率:薬剤タイプ別
  • 競合分析
  • R&D
  • 総市場分析

第7章 企業プロファイル

  • ABBOTT LABORATORIES
  • ARMETHEON INC.
  • ASTRAZENECA
  • BAXTER INTERNATIONAL
  • BAYER AG
  • BIOVASCULAR, INC.
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB COMPANY
  • CANYON PHARMACEUTICALS
  • CORNERSTONE THERAPEUTICS, INC.
  • CSL BEHRING
  • 第一三共
  • エーザイ
  • ELI LILLY
  • EMISPHERE TECHNOLOGIES
  • GENENTECH
  • GLAXOSMITHKLINE
  • GTC BIOTHERAPEUTICS
  • JOHNSON & JOHNSON
  • LIGAND PHARMACEUTICALS, INC.
  • MERCK
  • MERRION PHARMACEUTICALS, LTD.
  • MICROBIX BIOSYSTEMS, INC.
  • NOVARTIS
  • 小野薬品工業
  • 大塚製薬
  • PFIZER, INC
  • PORTOLA PHARMACEUTICALS
  • REGADO
  • SANOFI
  • SANTA CRUZ BIOTECHNOLOGY, INC.
  • SERVIER
  • THE MEDICINES COMPANY

第8章 掲載企業の全リスト

目次
Product Code: PHM119A

Abstract

REPORT HIGHLIGHTS

This report provides:

An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals

Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017

Breakdowns of the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors

Discussion of research and development of antithrombotic/anticoagulant treatments

Comprehensive company profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field.

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The objectives of the study are to present both a comprehensive look at antithrombotics/anticoagulant drugs for treating thrombotic disease and global market measurements of both the overall market and all possible market segments, and to forecast market and segment growth over the next five years.

REASONS FOR STUDY

This BCC study is presented to increase the awareness of antithrombotic/ anticoagulant drugs to treat thrombotic disease and other diseases that are linked to thrombotic disease. The study analyzes (1) select antithrombotic/anticoagulant drugs for treating various thrombotic diseases in coronary artery disease, peripheral vascular disease, valvular heart disease, congestive heart failure and many others; (2) the marketing of these drugs in the global market from different standpoints; and (3) the issues and trends affecting the market.

Antithrombotic/anticoagulant manufacturers, driven by both research breakthroughs and increased recognition of expanding market opportunities, have stepped up the pace of development of products. Because of the evolving nature of this important area of study, executives of product development for antithrombotic/anticoagulant drugs must remain ever vigilant of the changing environment and strive to keep abreast of new and currently used modalities in all facets of the market.

SCOPE OF STUDY

This report is a comprehensive business tool designed to provide an in-depth look at antithrombotic/anticoagulant drugs for various cardiovascular applications. The geographic scope of the report is global with a special emphasis on individual regions such as the United States, Europe, Japan and Rest of World. The report describes the industry, its relationship to the healthcare industry and its participants, and trends for the future.

Categories discussed in the report include:

  • Anticoagulants
  • Antiplatelets
  • Thrombin inhibitors

All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2012 to 2017 and assessing the competitors and competitor market shares.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary research sources, including executives, product managers, and clinical specialists in the congestive heart failure drug development arena. Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of thrombotic and cardiovascular disease.

Key information from published literature was used to conduct interviews with over 12 industry participants to validate and obtain expert opinions on current and future trends in the antithrombotic/anticoagulant drug market. Interviews were the primary basis for information regarding development of market size and were obtained by email and telephone. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

All market data pertain to the global market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year was 2012. Historical data are provided for 2011 and forecast data are provided for 2017. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2012 base year.

ANALYST CREDENTIALS

Mary Anne Crandall is an expert industry analyst specializing in the medical pharmaceutical and device industry for the last 20 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical and medical device industry. Ms. Crandall has extensive knowledge in the medical field, has an M.S. in psychology and is currently working on a PhD.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR STUDY
  • SCOPE OF STUDY
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY

  • Table Summary : TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017
  • Figure Summary : TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017

Chapter- 3: INDUSTRY OVERVIEW

  • THE CIRCULATORY SYSTEM
  • CONDITIONS
  • HEMOSTASIS (THE CLOTTING PROCESS)
  • DISEASES ASSOCIATED WITH THROMBOEMBOLISM
  • STENTS AND THROMBOSIS
  • DEMOGRAPHICS
  • VENOUS THROMBOEMBOLISM AND LIFESTYLE
  • VENOUS THROMBOEMBOLISM AND AIR TRAVEL

Chapter- 4: ANTICOAGULANTS

  • OVERVIEW
  • PRODUCTS
  • GLOBAL MARKET SIZE AND GROWTH
  • GROWTH BY GEOGRAPHIC REGION
  • GROWTH BY DRUG TYPE
  • COMPETITIVE ANALYSIS

Chapter- 5: ANTIPLATELETS

  • OVERVIEW
  • PRODUCTS
  • GLOBAL MARKET SIZE AND GROWTH
  • GROWTH BY GEOGRAPHIC REGION
  • GROWTH BY DRUG TYPE

Chapter- 6: THROMBIN INHIBITORS

  • OVERVIEW
  • PRODUCTS
  • GLOBAL THROMBIN INHIBITOR MARKET SIZE AND GROWTH
  • THROMBIN INHIBITOR GROWTH BY GEOGRAPHIC REGION
  • GROWTH BY DRUG TYPE
  • COMPETITIVE ANALYSIS
  • RESEARCH AND DEVELOPMENT
  • TOTAL MARKET ANALYSIS

Chapter- 7: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ARMETHEON INC.
  • ASTRAZENECA
  • BAXTER INTERNATIONAL
  • BAYER AG
  • BIOVASCULAR, INC.
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB COMPANY
  • CANYON PHARMACEUTICALS
  • CORNERSTONE THERAPEUTICS, INC.
  • CSL BEHRING
  • DAIICHI SANKYO COMPANY LTD
  • EISAI COMPANY, LTD.
  • ELI LILLY
  • EMISPHERE TECHNOLOGIES
  • GENENTECH
  • GLAXOSMITHKLINE
  • GTC BIOTHERAPEUTICS
  • JOHNSON & JOHNSON
  • LIGAND PHARMACEUTICALS, INC.
  • MERCK
  • MERRION PHARMACEUTICALS, LTD.
  • MICROBIX BIOSYSTEMS, INC.
  • NOVARTIS
  • ONO PHARMACEUTICAL CO., LTD
  • OTSUKA PHARMACEUTICAL CO., LTD.
  • PFIZER, INC
  • PORTOLA PHARMACEUTICALS
  • REGADO
  • SANOFI
  • SANTA CRUZ BIOTECHNOLOGY, INC.
  • SERVIER
  • THE MEDICINES COMPANY

Chapter- 8: A COMPLETE LISTING OF ALL THE COMPANIES IN THE REPORT

List of Tables

  • Summary Table : TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017
  • Table 1 : FACTORS PREDISPOSING TO PULMONARY EMBOLISM OF VIRCHOW'S TRIAD
  • Table 2 : TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050
  • Table 3 : HEART DISEASE DEATHS BY COUNTRY
  • Table 4 : U.S. STROKE DEMOGRAPHICS BY SELECTED CHARACTERISTICS, 2010
  • Table 5 : GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017
  • Table 6 : GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2012
  • Table 7 : FORECAST GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2017
  • Table 8 : GLOBAL MARKET SIZE OF ANTICOAGULANT DRUG REVENUES BY DRUG TYPE, THROUGH 2017
  • Table 9 : GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012
  • Table 10 : GLOBAL ANTICOAGULANT DRUG BY DRUG TYPE, 2017
  • Table 11 : TOTAL GLOBAL ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012
  • Table 12 : TOTAL GLOBAL ANTICOAGULANT DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE
  • Table 13 : TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTIPLATELET DRUGS, THROUGH 2017
  • Table 14 : TOTAL GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2012
  • Table 15 : FORECAST GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2017
  • Table 16 : GLOBAL MARKET SIZE OF ANTIPLATELET DRUG REVENUE BY DRUG TYPE, THROUGH 2017
  • Table 17 : GLOBAL ANTIPLATELET DRUG MARKET BY DRUG TYPE, 2012
  • Table 18 : GLOBAL ANTIPLATELET MARKET BY DRUG TYPE, 2017
  • Table 19 : TOTAL GLOBAL ANTIPLATELET DRUG MARKET COMPETITIVE ANALYSIS, 2012
  • Table 20 : GLOBAL ANTIPLATELET DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE
  • Table 21 : PROJECTED GLOBAL MARKET SIZE AND GROWTH BY REGION FOR THROMBIN INHIBITORS, THROUGH 2017
  • Table 22 : TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2012
  • Table 23 : TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2017
  • Table 24 : GLOBAL THROMBIN INHIBITOR MARKET REVENUE BY DRUG TYPE, THROUGH 2017
  • Table 25 : GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2012
  • Table 26 : GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2017
  • Table 27 : TOTAL GLOBAL THROMBIN INHIBITOR DRUG MARKET COMPETITIVE ANALYSIS, 2012
  • Table 28 : TOTAL GLOBAL THROMBIN INHIBITOR DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE
  • Table 29 : ANTITHROMBOTIC/ANTICOAGULANT TREATMENTS IN DEVELOPMENT, 2012
  • Table 30 : SIZE OF GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET REVENUE BY DRUG TYPE, THROUGH 2017
  • Table 31 : GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE, 2012
  • Table 32 : FORECAST GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE 2017
  • Table 33 : GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, THROUGH 2017
  • Table 34 : GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY GEOGRAPHIC REGION, 2012
  • Table 35 : GLOBAL ANTITHROMBOTIC/ANTICOAGULANT BY GEOGRAPHIC REGION, 2017
  • Table 36 : GLOBAL ANTITHROMBIN/ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012
  • Table 37 : GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE

List of Figures

  • Summary Figure : TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017
  • Figure SAMPLE FIGURE : TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017
  • Figure 1 : TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050
  • Figure 2 : GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017
  • Figure 3 : GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2012
  • Figure 4 : FORECAST GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2017
  • Figure 5 : GLOBAL MARKET SIZE OF ANTICOAGULANT DRUG REVENUE BY DRUG TYPE, 2011-2017
  • Figure 6 : GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012
  • Figure 7 : GLOBAL ANTICOAGULANT MARKET BY DRUG TYPE, 2017
  • Figure 8 : TOTAL GLOBAL ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012
  • Figure 9 : TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTIPLATELET DRUGS, 2011-2017
  • Figure 10 : TOTAL GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2012
  • Figure 11 : FORECAST GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2017
  • Figure 12 : GLOBAL MARKET SIZE OF ANTIPLATELET DRUG REVENUE BY DRUG TYPE, THROUGH 2017
  • Figure 13 : GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012
  • Figure 14 : GLOBAL ANTIPLATELET MARKET BY DRUG TYPE, 2017
  • Figure 15 : TOTAL GLOBAL ANTIPLATELET DRUG MARKET COMPETITIVE ANALYSIS, 2012
  • Figure 16 : PROJECTED GLOBAL MARKET SIZE AND GROWTH BY REGION FOR THROMBIN INHIBITORS, 2011-2017
  • Figure 17 : TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2012
  • Figure 18 : TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2017
  • Figure 19 : GLOBAL THROMBIN INHIBITOR MARKET REVENUE BY DRUG TYPE, 2011-2017
  • Figure 20 : GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2012
  • Figure 21 : GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2017
  • Figure 22 : TOTAL GLOBAL THROMBIN INHIBITOR DRUG MARKET COMPETITIVE ANALYSIS, 2012
  • Figure 23 : SIZE OF GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET REVENUE BY DRUG TYPE, 2011-2017
  • Figure 24 : GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE, 2012
  • Figure 25 : FORECAST GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY DRUG TYPE, 2017
  • Figure 26 : GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, 2011-2017
  • Figure 27 : GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY GEOGRAPHIC REGION, 2012
  • Figure 28 : GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY DRUG TYPE, 2017
  • Figure 29 : GLOBAL ANTITHROMBOTIC/ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012
Back to Top